FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Sesen Bio Strengthens Executive Leadership Team as the Company Nears the Potential Approval of Vicineum”
Sesen Bio (NASDAQ: SESN) climbed over 6% in premarket trading after the company announced the expansion of its executive leadership team with the hiring of John Knighton as Vice President and Chief Compliance Officer
Additionally, the Company’s Biologics License Application for Vicineum for the treatment of BCG-unresponsive non-muscle invasive bladder cancer, is currently under Priority Review with the US FDA with a target Prescription Drug User Fee Act date of August 18th, 2021.
Sesen Bio, Inc. is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer. The Company’s lead program, Vicineum™, also known as oportuzumab monatox, is currently in the follow-up stage of a Phase 3 registration trial for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). In February 2021, the FDA accepted the Company’s BLA file for Vicineum for the treatment of BCG-unresponsive NMIBC and granted the application Priority Review with a target PDUFA date of August 18, 2021.
For more information, please visit: Sesen Bio
About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.